序号 | 标题 | 次数 | 作者 | 发布时间 |
---|---|---|---|---|
69706 | Ald-CH2-PEG5-Boc | 57 | zyl | 2024-12-13 |
69707 | 通过构建shRNA慢病毒质粒实现基因的敲减,慢病毒载体的发展过程 | 478 | axc | 2024-12-13 |
69708 | Fmoc-Gly-NH-CH2-O-Cyclopropane-CH2COOH | 67 | zyl | 2024-12-13 |
69709 | Gly-NH-CH2-Boc | 88 | zyl | 2024-12-13 |
69710 | Difluorocyclooctyne-CH2-benzoic acid | 85 | zyl | 2024-12-13 |
69711 | NH2-PEG2-CH2-Boc | 93 | zyl | 2024-12-13 |
69712 | shRNA慢病毒载体构建及细胞系筛选 | 407 | axc | 2024-12-13 |
69713 | Hydroxy-PEG4-(CH2)2-Boc | 71 | zyl | 2024-12-13 |
69714 | Thalidomide-5-O-CH2-COOH | 96 | zyl | 2024-12-13 |
69715 | Thalidomide-NH-CH2-COOH | 98 | zyl | 2024-12-13 |
69716 | Amino-PEG10-CH2-Boc | 105 | zyl | 2024-12-13 |
69717 | Hydroxy-PEG6-CH2-Boc | 59 | zyl | 2024-12-13 |
69718 | Tos-PEG4-CH2-Boc | 69 | zyl | 2024-12-13 |
69719 | m-PEG4-CH2-alcohol | 59 | zyl | 2024-12-13 |
69720 | β-Naphthoflavone-CH2-OH | 110 | zyl | 2024-12-13 |
69721 | 利用慢病毒快速构建IPS稳转株,定制服务 | 114 | axc | 2024-12-13 |
69722 | Methyl isonicotinate-(CH2)2-COOH | 64 | zyl | 2024-12-13 |
69723 | HO-PEG24-CH2COOtBu | 58 | zyl | 2024-12-13 |
69724 | Hydroxy-PEG10-CH2-Boc | 113 | zyl | 2024-12-13 |
69725 | Fmoc-Gly-NH-CH2-acetyloxy | 76 | zyl | 2024-12-13 |
69726 | Thalidomide-5-CH2-NH2 hydrochloride | 80 | zyl | 2024-12-13 |
69727 | MC-Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH-d5 | 70 | zyl | 2024-12-13 |
69728 | 通过慢病毒介导的基因过表达,定制服务,实验步骤 | 117 | axc | 2024-12-13 |
69729 | 基因敲低、敲除、过表达载体的构建 | 1085 | axc | 2024-12-13 |
69730 | 质粒以及慢病毒的基因过表达方法 | 628 | axc | 2024-12-13 |
69731 | CRISPR KI技术构建基因过表达细胞株 | 176 | axc | 2024-12-13 |
69732 | CRISPRa系统构建基因过表达细胞株,CRISPRa技术优势 | 164 | axc | 2024-12-13 |
69733 | PB转座子系统构建基因过表达细胞,技术介绍 | 287 | axc | 2024-12-13 |
69734 | 慢病毒介导的稳定细胞株构建流程 | 457 | axc | 2024-12-13 |
69735 | 慢病毒载体介导过表达和敲低细胞株的建立 | 221 | axc | 2024-12-13 |
69736 | 七肽DOTA-YLYEIAR,1262403-90-6 | 106 | h | 2024-12-12 |
69737 | DOTA-CH2-Ph-azide(HCl salt) | 134 | h | 2024-12-12 |
69738 | NOTA-PEG-TAT,大环配体NOTA-聚乙二醇-TAT | 90 | h | 2024-12-12 |
69739 | DOTA-Lys-Cys-Acid,1180007-00-4 | 105 | h | 2024-12-12 |
69740 | DOTA-NHS ester,CAS170908-81-3 | 81 | h | 2024-12-12 |
69741 | C18-PEG-Lactoferrin; 十八烷基-聚乙二醇-乳铁蛋白 | 294 | kx | 2024-12-12 |
69742 | C18-PEG-Glucose ;十八烷基-聚乙二醇-葡萄糖 | 148 | kx | 2024-12-12 |
69743 | C18-PEG-NPC ;十八烷基-聚乙二醇-NPC | 138 | kx | 2024-12-12 |
69744 | 1262403-92-8,十三肽DOTA-LGEYGFQNALIVR | 89 | h | 2024-12-12 |
69745 | 七肽DOTA-YLYEIAR,1262403-91-7 | 78 | h | 2024-12-12 |
69746 | C10-SS-PEG-DBCO | 70 | kx | 2024-12-12 |
69747 | Biotin-PEG-C14, 生物素聚乙二醇C14 | 59 | kx | 2024-12-12 |
69748 | NH2-PEG3400-C16 palmitic acid ,氨基-聚乙二醇-棕榈酸 | 81 | kx | 2024-12-12 |
69749 | NH2-PEG350-C16 palmitic acid ,氨基-聚乙二醇-棕榈酸 | 81 | kx | 2024-12-12 |
69750 | mPEG-se-se-C16 ,甲氧基-聚乙二醇-双硒键-棕榈酸 | 111 | kx | 2024-12-12 |